- Home
- BCTX vs CRIS Comparison
BCTX vs CRIS Comparison
Compare BCTX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- CRIS
- Stock Information
- Founded
- BCTX 2014
- CRIS 2000
- Country
- BCTX Canada
- CRIS United States
- Employees
- BCTX N/A
- CRIS N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCTX Health Care
- CRIS Health Care
- Exchange
- BCTX Nasdaq
- CRIS Nasdaq
- Market Cap
- BCTX 23.5M
- CRIS 21.3M
- IPO Year
- BCTX N/A
- CRIS 2000
- Fundamental
- Price
- BCTX $3.11
- CRIS $2.28
- Analyst Decision
- BCTX Strong Buy
- CRIS Strong Buy
- Analyst Count
- BCTX 1
- CRIS 2
- Target Price
- BCTX $32.00
- CRIS $16.50
- AVG Volume (30 Days)
- BCTX 359.2K
- CRIS 75.5K
- Earning Date
- BCTX 06-16-2025
- CRIS 07-31-2025
- Dividend Yield
- BCTX N/A
- CRIS N/A
- EPS Growth
- BCTX N/A
- CRIS N/A
- EPS
- BCTX N/A
- CRIS N/A
- Revenue
- BCTX N/A
- CRIS $11,202,000.00
- Revenue This Year
- BCTX N/A
- CRIS N/A
- Revenue Next Year
- BCTX N/A
- CRIS $10.67
- P/E Ratio
- BCTX N/A
- CRIS N/A
- Revenue Growth
- BCTX N/A
- CRIS 14.17
- 52 Week Low
- BCTX $2.78
- CRIS $1.02
- 52 Week High
- BCTX $29.40
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- BCTX 44.63
- CRIS 50.37
- Support Level
- BCTX $2.78
- CRIS $2.11
- Resistance Level
- BCTX $3.16
- CRIS $2.26
- Average True Range (ATR)
- BCTX 0.19
- CRIS 0.20
- MACD
- BCTX -0.01
- CRIS -0.04
- Stochastic Oscillator
- BCTX 40.24
- CRIS 16.85
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.